Cailin Conner

DocwireNews

Gout is a painful and chronic form of arthritis that affects millions of people worldwide. While there are medications available to manage gout symptoms, some patients experience uncontrolled gout, where conventional treatments fail to provide adequate relief. &ldquo;Pegloticase (PEGylated uricase) is often the last remaining treatment option for patients with refractory or uncontrolled gout, which can markedly impact patient health and quality of life,&rdquo; researchers from the MIRROR RCT study wrote, which was published in ACR Open Rheumatology. In their study, they aimed to evaluate the safety and efficacy of combining methotrexate (MTX) with pegloticase to further enhance treatment outcomes.MIRROR RCT was a randomized, double-blind, placebo-controlled, multicenter trial that spanned over 12 months. The study included patients with uncontrolled gout who had a serum urate (SU) level of at least 7 mg/dL, had failed or were intolerant to oral urate-lowering therapy, and presented with 1 or more gout symptoms such as tophi (uric acid deposits), frequent flares, or gouty arthropathy (joint damage due to gout).The participants were randomly assigned to 1 of 2 groups: one receiving pegloticase infusions every 2 weeks along with oral MTX (15 mg/week), and the other receiving pegloticase infusions with a placebo. The primary endpoint of the study was the proportion of responders, defined as patients achieving an SU level below 6 mg/dL for at least 80% of the examined month, at month 6. Secondary endpoints included response rates at months 9 and 12, resolution of tophi, mean SU reduction, and the duration of pegloticase treatment.The results of the study revealed significant benefits of combining MTX with pegloticase. At month 12, the response rate among patients receiving the combination therapy was 60.0% compared with 30.8% in the placebo group, representing a substantial difference of 29.1%. Moreover, the rate of discontinuation of pegloticase due to elevated SU levels was much lower in the MTX group (22.9%) compared with the placebo group (63.3%). Additionally, the combination therapy demonstrated improved resolution of tophi, with 53.8% of patients in the MTX group achieving complete resolution compared with 31.0% in the placebo group at week 52.The findings also indicated that the benefits of the combination therapy continued to increase beyond the sixth month, suggesting a sustained therapeutic effect. The pharmacokinetic and immunogenicity data showed that the exposure to pegloticase was higher, and the development of antibodies against the drug was lower when administered with MTX . Importantly, the safety profile of the combination therapy was comparable to that of pegloticase alone, with no infusion reactions reported after 24 weeks.Per the researchers, &ldquo;In conclusion, the 12-month results from the MIRROR RCT trial confirm increased urate-lowering response rate durability through month 12 of pegloticase [plus] MTX cotherapy versus pegloticase monotherapy.&rdquo;&nbsp;Source: <a href="https://onlinelibrary.wiley.com/doi/10.1002/acr2.11578" target="_blank" rel="noopener">ACR Open Rheumatology</a>

Jordana Jampel

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Latest News

Study Shows the Benefits of Methotrexate in Combination With Pegloticase for Treating Uncontrolled Gout

Gout

Methotrexate plus pegloticase for the treatment of uncontrolled gout resulted in higher response rates, improved resolution of tophi, and sustained therapeutic benefits.

Study Shows the Benefits of Methotrexate in Combination With Pegloticase for Uncontrolled Gout

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe